Ironwood Pharmaceuticals | IRWD - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Acadia Pharmaceuticals USD 956.47M 105.02M 2026-06
Agios Pharmaceuticals USD 99.65M 13.95M 2026-06
Akebia Therapeutics USD 155.55M 7.1M 2026-06
Almirall EUR 337.77M 14.83M 2025-12
Alnylam Pharmaceuticals USD 1.71B 2.46M 2026-06
Amarin USD 143.56M 12.5M 2026-06
Ardelyx USD 31.21M 36.79M 2026-03
Astellas Pharma JPY 281.6B 93.23B 2026-03
AstraZeneca USD 4.89B 2.67B 2026-06
Charles River Laboratories USD 192.02M 195K 2026-06
Coherus Biosciences USD 82.92M 32.32M 2026-06
Emergent BioSolutions USD 111.7M 23.9M 2023-12
Halozyme Therapeutics USD 163.14M 146.61M 2026-06
Incyte USD 3.98B 33.45M 2026-06
Ironwood Pharmaceuticals USD 220.47M 5.01M 2026-03
Karyopharm Therapeutics USD 90.85M 30.31M 2026-03
Lexicon Pharmaceuticals USD 38.09M 3.76M 2026-03
MacroGenics USD 66.52M 9.3M 2026-03
Moderna USD 1.72B 185M 2026-06
Myriad Genetics USD 115.2M 9.2M 2026-06
Pacira USD 205.88M 61.57M 2026-06
PTC Therapeutics USD 1.05B 215.9M 2026-06
Puma Biotechnology USD 53.52M 1.14M 2025-09
Sarepta Therapeutics USD 571.15M 106.7M 2026-06
Takeda JPY 460.98B 134.07B 2026-06
Ultragenyx Pharmaceutical USD 125M 50M 2026-06
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12